Table 2.
Dosage of Pentosan Polysulfate
| Dosage | Mean | PPS-Retinopathy (n=33) | No PPS-Retinopathy (n=115) | P-value |
|---|---|---|---|---|
| Cumulative PPS Dose (grams) | 1030g±904 | 1600±849 | 864±852 | <0.0001 |
| Duration of PPS Use (years) | 8.83±6.84 | 13.54±6.64 | 7.48±6.30 | <0.0001 |
| Duration of Interstitial Cystitis (years) | 16.1±11.8 | 16.1±6.91 | 10.6±7.06 | 0.0004 |
| Dose per day (mg/d) | 320±127 | 332±91 | 316±136 | 0.32 |
| Mg/kg/d | 4.59±2.28 | 4.74±1.97 | 4.55±2.38 | 0.47 |
| Mg/BMI/d | 12.5±5.96 | 12.6±5.29 | 12.5±6.16 | 0.78 |
| Mg/BSA/d | 1.78±0.79 | 1.85±0.609 | 1.76±0.83 | 0.42 |
| Mg/LBW/d | 6.36±2.88 | 6.71±2.22 | 6.27±3.04 | 0.24 |
Notes: Patients in the pentosan polysulfate sodium (PPS) group had higher cumulative dosages and longer duration of use compared to the no-PPS-associated retinopathy group. There was no difference between the groups based on the patient’s weight (in kilograms), body mass index (BMI), body surface area (BSA), or lean body weight (LBW). None of the values had normal distributions (Shapiro–Wilks test P<0.001), and the Mann–Whitney test was used for the calculations.